Document Detail


Effects of transglucosidase on diabetes, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes: a 12-week, randomized, double-blind, placebo-controlled trial.
MedLine Citation:
PMID:  22098444     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
In this 12-week, randomized, double-blind, placebo-controlled trial, the efficacy and safety of transglucosidase (TGD) were compared with placebo in patients with type 2 diabetes mellitus (T2DM). At 12 weeks, TGD 300 mg/d and TGD 900 mg/d significantly reduced HbA1c (0.18% and 0.21%) and insulin concentration (19.4 and 25.0 pmol/L), respectively, versus placebo. TGD 300 mg/d and TGD 900 mg/d also significantly reduced LDL-C (0.22 and 0.17 mmol/L, respectively). TGD 900 mg/d significantly reduced triglyceride by 0.24 mmol/L and diastolic blood pressure by 8 mmHg. Placebo was associated with a significant increase from baseline in BMI, ALT, and AST (0.17 kg/m(2) , 3, and 2 U/L, respectively), whereas TGD was not. TGD 300 mg/d significantly increased HMW adiponectin by 0.6 μg/mL. Adverse events did not differ significantly between the groups. TGD resulted in lowering of HbA1c and blood insulin level, and improvements in metabolic and cardiovascular risk factors in T2DM.
Authors:
Makoto Sasaki; Kenro Imaeda; Naotsuka Okayama; Tatsuo Mizuno; Hiromi Kataoka; Takeshi Kamiya; Eiji Kubota; Naotaka Ogasawara; Yasushi Funaki; Mari Mizuno; Akihito Iidamd; Chiho Goto; Satoshi Koikeda; Kunio Kasugai; Takashi Joh
Related Documents :
2006934 - Histocompatibility antigen subtypes in black women with class a1 or class gb diabetes m...
20706994 - Maternal diabetes and renal agenesis/dysgenesis.
9259924 - The rubenesque pregnancy: a progression towards higher blood pressure correlates with a...
11132584 - Diagnosis of macrosomia in the postdates population: combining sonographic estimates of...
15317614 - A case of secondary diabetes mellitus with acromegaly improved by pioglitazone.
8188514 - Selection of quarter horses affected with hyperkalemic periodic paralysis by show judges.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-11-19
Journal Detail:
Title:  Diabetes, obesity & metabolism     Volume:  -     ISSN:  1463-1326     ISO Abbreviation:  -     Publication Date:  2011 Nov 
Date Detail:
Created Date:  2011-11-21     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100883645     Medline TA:  Diabetes Obes Metab     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 Blackwell Publishing Ltd.
Affiliation:
Department of Gastroenterology, Aichi Medical University School of Medicine Department of Gastroenterology and Metabolism, Nagoya City University Graduate School of Medical Sciences Nagoya Bunri University Amano Enzyme Inc.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Liver protein profiling in chronic hepatitis C: Identification of potential predictive markers for i...
Next Document:  Functional magnetic resonance imaging in awake animals.